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ABSTRACT 
Myocarditis, often triggered by viral infection, may lead to heart auto-immunity and dilated 
cardiomyopathy. What determines the switch between disease resolution and progression is 
however incompletely understood. We show that pharmacological inhibition of STAT3, the main 
mediator of IL-6 signaling and of Th17 cell differentiation, protects mice from the development of 
Experimental Auto-immune Myocarditis reducing liver production of the complement component 
C3, and can act therapeutically when administered at disease peak. Further, we demonstrate that 
STAT3 is sufficient when constitutively active for triggering the onset of immune-mediated 
myocarditis, involving enhanced complement C3 production and IL-6 signalling amplification in 
the liver. Disease development can be prevented by C3 depletion and IL-6 receptor neutralization. 
This appears to be relevant to disease pathogenesis in humans, since acute myocarditis patients 
display significantly elevated circulating IL-6 and C3 levels and activated heart STAT3. Thus, 
aberrant IL-6/STAT3-mediated induction of liver acute phase response genes including C3, which 
occurs as a consequence of pre-existing inflammatory conditions, might represent an important 
factor determining the degree of myocarditis and its clinical outcome.  
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INTRODUCTION 
The transcription factor Signal Transducer and Activator of Transcription (STAT)3 was first 
isolated as Acute Phase Response Factor, essential for liver transcriptional responses to acute 
inflammation (Alonzi et al., 2001), and was later shown to be involved in the signalling of a wide 
variety of cytokines, growth factors and oncogenes (Poli et al., 2003). Depending on its modalities, 
STAT3 activation can either be beneficial or pathogenic in a number of conditions. For example, 
cytokine-mediated activation, controlled by tight negative feedback mechanisms, is required for 
mammary gland involution (Chapman et al., 1999), contributes to stimulate efficient immune 
reactions (Fornek et al., 2006) and plays a protective role in myocardial infarction and ischemia 
(Hilfiker-Kleiner et al., 2004; Hilfiker-Kleiner et al., 2007). On the other hand, its constitutive 
activity is believed to exert pro-oncogenic functions (Demaria et al., 2012; Yu et al., 2009). Knock-
in mice where the wild type STAT3 allele was replaced by its constitutively active artificial mutant 
form, STAT3C, were recently generated in our laboratory.  These mice display low but continuous 
STAT3 activity in all tissues, which led to accellerated oncogene-mediated breast tumorigenesis 
and increased metastasis, altered energy metabolism and predisposition to tumor transformation 
(Barbieri et al., 2010; Demaria et al., 2010; Demaria et al., 2012). Aberrant STAT3 activation often 
occurs downstream of chronic IL-6 production, which gives rise to a feed-forward loop leading to 
inflammation-driven tumourigenesis (Li et al., 2011). Indeed, both systemic- and locally-sustained 
IL-6 production are considered a hallmark of chronic inflammation, which can in turn also lead to 
the development of auto-immunity (Camporeale and Poli, 2012). Moreover, IL-6 is required to 
initiate the differentiation of Th17 cells, a subset of IL-17-producing pro-inflammatory CD4
+
 T 
helper cells (Veldhoen et al., 2006). Th17 cell differentiation, which is strongly STAT3-dependent 
(Harris et al., 2007), is in turn implicated in the pathogenesis of several auto-immune diseases 
(Steinman, 2007). Additionally, both Th17 cells and IL-6 have been shown to participate in the 
pathogenesis of experimental auto-immune myocarditis (EAM) (Eriksson et al., 2003; Yamashita et 
al., 2011), which can be triggered in the mouse by immunization with -cardiac myosin peptide 
(Pummerer et al., 1996).  
 Myocarditis is an inflammatory heart condition that can be caused by common viral 
pathogens with a direct myopathic effect such as, for example, coxsackievirus B3 virus (CVB3) 
(Rose, 2009), and is characterized by an inflammatory infiltrate composed of abundant myeloid 
cells and CD4
+
 T lymphocytes, features that are reproduced in the EAM murine model (Baldeviano 
et al., 2010; Nindl et al., 2012). The infection can trigger a potent T-cell mediated immune response 
characterized by high titres of IgG auto-antibodies to cardiac -myosin and other heart proteins 
(Caforio et al., 2002). Immune-mediated myocarditis can lead to dilated cardiomyopathy (DCM) in 
about one third of the cases, and represents a frequent cause of cardiac failure particularly in young 
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adults (Schultheiss et al., 2011). IL-17 has recently been shown to play a pathogenic role in post-
myocarditis remodeling and DCM development in mice, suggesting that excessive Th17 
lymphocytes activity may be one of the factors determining disease progression (Baldeviano et al., 
2010; Nindl et al., 2012). Which other factors determine the switch between disease resolution and 
progression is however not well understood.  
The role of STAT3 in cardiac inflammation has been assessed by expressing the negative 
feedback factor SOCS3 or by deleting STAT3, both specifically in cardiomyocites. Similar to its 
known beneficial functions during myocardial infarction, physiological activity of STAT3 in the 
heart plays a protective role in a model of myocarditis mediated by CVB3 infection (Lindner et al., 
2012; Yajima et al., 2006). In contrast, enhanced heart-specific STAT3 activity led to increased 
inflammation upon myocardial infarction (Hilfiker-Kleiner et al., 2010), underlining the importance 
of a correct control of STAT3 activation. 
 Here we show that pharmacological inhibition of STAT3, the main mediator of IL-6 
signaling and of Th17 cell differentiation, protects mice from the development of EAM and can 
improve disease outcome when administered after disease development. Further, we demonstrate 
that STAT3 is sufficient when constitutively active for triggering the onset of auto-immune 
myocarditis, involving enhanced complement C3 production and IL-6 signalling amplification in 
the liver. Disease development can be prevented by C3 depletion and IL-6 receptor neutralization. 
Thus, uncontrolled systemic STAT3 activation appears to represent a crucial factor in the 
pathogenesis of immune-mediated myocarditis.  
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RESULTS 
 
STAT3 inhibition abrogates the development of EAM 
STAT3 is found aberrantly activated, downstream of IL-6, in a number of chronic inflammatory 
conditions leading to tumor transformation or auto-immunity (Camporeale and Poli, 2012; Li et al., 
2011). To assess the role of STAT3 in the development of immune-mediated myocarditis, we 
utilized the well-established EAM model, where heart disease is induced by means of immunization 
with an -myosin peptide (Pummerer et al., 1996). EAM was induced in Balb/C mice, treated or 
not with the specific STAT3 inhibitor SF-1-066 (Zhang et al., 2010). STAT3 inhibition was 
effective (Supporting Information Fig S1A and B) and resulted in protection of mice from 
myocarditis, as shown by the significantly reduced percentages of heart-infiltrating CD11b
+ 
cells at 
sacrifice (Fig. 1 A) and by virtually undetectable lymphocyte infiltration as assessed by H&E and 
anti-CD18 staining (Fig. 1 B). Particularly significant was the absence of fibrosis, a marker of heart 
damage, evidenced by the failure of picrosirius red to detect collagen fibrils in the SF-1-066-treated 
mice (Fig. 1 B). Up-regulation of the complement component C3, a plasma protein whose main site 
of production is the liver, is know to play a pathogenic role in EAM (Eriksson et al., 2003; Kaya et 
al., 2001). STAT3 inhibition completely abrogated both the up-regulation of C3 and the 
development of anti-myosin antibodies, which reached a peak at day 21 post-immunization in the 
control mice (Fig. 1 C). Disease protection correlated with impaired myosin-specific CD4
+
 T 
lymphocytes responses, as assessed in vitro in a myosin-specific proliferation assay (Fig. 1 D). 
These data clearly demonstrate that STAT3 plays a crucial role in the pathogenesis of EAM, by 
both enhancing the activation of CD4
+
 T lymphocytes and up-regulating the production of C3 in the 
liver.  
 To assess whether STAT3 inhibition could also act therapeutically by preventing the 
progression of autoimmune myocarditis to dilated cardiomyopathy (DCM), known to occur after 
day 21 and to peak at day 42 (Cihakova and Rose, 2008), EAM was induced in Balb/C mice 
followed by administration of the SF-1-066 inhibitor starting at day 21 post-immunization. All mice 
developed EAM as assessed by the appearance of anti-myosin antibodies and the up-regulation of 
circulating C3 levels (Supporting Information Fig. S1C and D). Echocardiographic analysis of the 
left ventricle was periodically performed to assess diastolic and systolic function. STAT3 inhibition 
could afford a significant improvement of the diastolic function at day 42 post-immunization, when 
DCM is known to reach its peak (Cihakova and Rose, 2008). While all mice displayed similar 
levels of restrictive cardiomyopathy at days 21 and 30, assessed as grade of diastolic dysfunction as 
described in the Methods section, by day 42 dysfunction was significantly reduced in SF-1-066-
treated mice (Fig. 1 E). This correlated with reduced ventricular systolic and diastolic dysfunction, 
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as shown by a lower Myocardial Performance Index (MPI) (Fig. 1 F). MPI failed to increase 
significantly in STAT3-inhibited mice, and at day 42 was indistinguishable from that observed 
before disease induction. Moreover, while control mice displayed a significant reduction of the 
fractional shortening (FS) at day 42, FS failed to significantly decrease in the SF-1-066-treated 
mice, suggesting a better preservation of contractile function (Fig. 1 G and Supporting Information 
Fig. S1E). Taken together, these data suggest that STAT3, in addition to play a central role in EAM 
onset, is also crucial for its progression to heart failure and DCM.  
 
Aggressive myocarditis in knock-in mice expressing constitutively active STAT3 
Knock-in Stat3
C/C
 mice, expressing the constitutively active mutant form STAT3C (Barbieri et al., 
2010), were born with mendelian ratios and displayed slightly reduced body weight at birth and 
blunted growth curves when compared to wild type (WT) littermates, followed by weight loss and 
death between four and six weeks of age (Fig. 2, A and B). In contrast, heterozygous Stat3
C/WT
 mice 
displayed normal growth rates and life span. Post-mortem examination revealed massive leukocyte 
infiltration in the heart, confirmed by immunohistochemical (IHC) staining with the pan-leukocyte 
marker CD18 (Fig. 2 D). Almost 60% of the infiltrating population was composed of CD11b
+
 
myeloid cells, mostly positive for the granulocyte marker Gr1 (Fig. 2 C). We established an 
arbitrary threshold of 10% increase in CD11b
+
 cells in the heart of Stat3
C/C
 versus Stat3
WT/WT
 mice 
in order to define two groups, i.e. infiltrated/sick versus non-infiltrated/healthy Stat3
C/C
 mice. 
CD11b
+
/Gr1
+
 cells were also significantly expanded in the bone marrow (BM) and the peripheral 
blood of both infiltrated (i.) and non-infiltrated (n.i.) Stat3
C/C
 mice (BM, 56.1±5.7 % n.i., 
51.8±3.9% i., compared to 33.8±2.1% in the Stat3
WT/WT
 mice; blood, 54.3±4.1% n.i., 65.0±4.4% i., 
versus 22.9±2.6 in the wild type controls). Myeloperoxidase-positive granulocytes, CD4
+
 
lymphocytes and MAC3
+
 macrophages were detected by IHC in infiltrated heart sections, together 
with a strong increase of tyrosine-phosphorylated STAT3 (Fig. 2 D), and of pro-inflammatory 
cytokine and chemokine mRNAs in the heart (Supporting Information Fig S2). Heart infiltration 
correlated with cardiac damage, as shown by the marked reparative fibrosis evidenced by 
picrosirius red staining of collagen fibrils (Fig. 2 D). Immunofluorescence (IF) analysis showed 
increasing numbers of Gr1
+
 cells in Stat3
C/C
 mice already starting from week 2 of age, followed by 
CD4
+
 T cell accumulation, detectable from week 3 (Fig. 3, A and B). Of note, it was only possible 
to detect small foci of leukocyte infiltration in other organs such as the liver, the spleen and the 
lymphnodes, but not the skeletal muscle, showing that the dramatic inflammation observed is 
specific to heart striated muscle and ruling out the involvement of a systemic inflammatory disease 
(Supporting Information Table I). 
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Additionally we analysed connexin 43 (cx43), the major component of gap junctions in the 
adult heart, whose decrease or delocalization is an established marker of cardiac suffering and heart 
failure (Fernandez-Cobo et al., 1999; Jansen et al., 2012). The cx43 signal, whilst initially 
comparable with wild type mice, decreased in the hearts of Stat3
C/C
 mice from 3 weeks of age 
becoming progressively dispersed (Fig. 3 C), suggesting that heart tissue organization, initially 
normal, becomes disorganized as a consequence of inflammation, detected at two weeks of age with 
infiltrating Gr1
+
 cells (Fig. 3 B). This was also confirmed by the irregular α-actinin staining that 
reveals progressive degradation of cell shape, particularly around the more heavily infiltrated 
regions (Fig. 3). The described heart damage in the Stat3
C/C
 mice clearly represents a phenotype of 
ongoing myocarditis, starting to lead to altered heart functionality as judged by echocardiography, 
since fractional shortening appeared to be significantly reduced (Supporting Information Table II). 
 
Myocarditis development in Stat3
C/C 
mice correlates with heart auto-immunity 
Western blot analysis of whole heart extracts and immunofluorescence (IF) staining of isolated 
adult myocytes with sera derived from diseased Stat3
C/C 
mice showed strong reactivity against 
proteins of the heart but not of other tissues including skeletal muscle, suggesting auto-immunity 
against heart components (Fig. 4, A and B). Notably, there was a good correlation between sera 
reactivity and degree of infiltration, whilst sera from non infiltrated Stat3
C/C 
and wild type mice 
were equivalent. Mass spectrometry analysis of cardiac extracts immunoprecipitated with pooled 
sera from Stat3
C/C 
mice identified myosin alpha heavy chain (Myh6), the major component of adult 
heart myosin, and myosin binding protein C3 (MyBP-C3) as the main recognized antigens (Fig. 4 
C). Results were confirmed using specific anti-Myh6 and anti-MyBP-C3 antibodies (Fig. 4 D). 
Anti-myosin alpha chain antibody titres correlated well with heart infiltration, as indicated by 
ELISA detection of α-myosin-specific IgG1s (Fig. 4 E). This assay was then routinely used to 
follow disease progression prior to post-mortem examination. 
 
Both hematopoietic and non-hematopoietic cells contribute to disease development 
CD4
+
 Th17 lymphocytes are known to play a role in EAM pathogenesis (Rangachari et al., 2006; 
Sonderegger et al., 2006) and to require STAT3 for their differentiation (Harris et al., 2007; Yang et 
al., 2007). Th17 cells were significantly more abundant in the spleen of Stat3
C/C 
mice compared to 
their wild type counterparts (Fig. 5 A), and naïve spleen-derived CD4
+
 cells from Stat3
C/C
 mice 
exhibited a three-fold enhanced ability to differentiate towards the Th17 lineage as compared to 
controls (Fig. 5 B). Further, when treated with TGF in the absence of IL-6, only CD4+ Stat3C/C 
cells could differentiate, albeit at low efficiency, into IL-17-producing cells, suggesting that STAT3 
constitutive activity can partly override the need for IL-6 in Th17 differentiation (Fig. 5 C). In 
 8 
agreement with the expanded Th17 population, the mRNAs for RORT and IL-23 were 
significantly elevated in the spleen of Stat3
C/C
 mice (Fig. 5 D). Accordingly IL-17, already 
displaying an increasing trend at the mRNA level in the heart (Supporting Information Fig S2), was 
detected by IF in the hearts of Stat3
C/C 
mice from 3 weeks of age (Fig. 5 E), correlating with the 
appearance of CD4
+
 cells and increasing with disease progression. Thus, constitutively active 
STAT3 enhances Th17 function, which in turn might contribute to exacerbate myocarditis by 
maintaining inflammation and increasing tissue damage. To assess the importance of IL-17 in our 
system, we treated Stat3
C/C
 mice with neutralizing anti-IL-17A antibodies or with control IgGs. 
Only two out of seven treated mice (25%) displayed increased survival (up to 60 days of age, Fig. 5 
F). IL-17 neutralization only moderately decreased leukocyte infiltration and fibrosis in surviving, 
but not in succumbing, mice (Supporting Information Fig S3A). Anti-myosin antibody levels and 
heart infiltration by CD4
+ 
cells were significantly decreased in the surviving mice, but comparable 
to the untreated mice in the succumbing animals (Supporting Information Fig S3B and Fig. 5G). 
These observations suggest a limited role for Th17 cells in our model. In contrast, CD4 depletion -
by means of neutralizing anti-CD4 antibodies- could rescue 50% of the Stat3
C/C 
mice from death up 
to 60 days of age, when they were sacrificed for analysis (Fig. 5 H and Supporting Information Fig 
S3C-E). Surviving anti-CD4-treated mice developed a significantly milder disease, with strongly 
reduced heart infiltration, tissue damage and auto-antibody levels (Fig. 5 I and Supporting 
Information Fig S3C and D). The discrepancy between the results obtained with IL-17 
neutralization and CD4 depletion may be explained by a differential efficiency of the two 
treatments. Additionally, other CD4
+
 cell populations may be involved in myocarditis development 
and outcome. Indeed, Th1 cells percentages and in vitro differentiation potential are preserved in 
the Stat3
C/C
 mice (Supporting Information Fig S3F and G), and the number of spleen-derived Th2 
cells is significantly increased (Supporting Information Fig S3F). This may be a consequence of in 
vivo Th17 cells expansion (Stritesky et al., 2011), as the in vitro Th2 differentiation potential is 
instead normal (Supporting Information Fig S3H).  
Since the rescue obtained by CD4 depletion was only partial and the STAT3C allele is 
expressed also in non hematopoietic cells, we decided to assess the relative contribution to disease 
development of hematopoietic versus non-hematopoietic cells via the generation of bone marrow 
chimeras. First, lethally irradiated Stat3
WT/WT 
mice were reconstituted with Stat3
C/C 
bone marrow 
cells (C->WT). These mice developed mild myocarditis, surviving for up to 60 days of age (Fig. 6 
A). Heart infiltration by CD18
+
 cells, fibrosis and circulating auto-antibody levels were reduced 
with respect to controls, i.e. Stat3
C/C
 mice reconstituted with Stat3
C/C 
bone marrow cells (C->C), 
whilst the percentage of infiltrating CD11b
+
 cells was similar (Fig. 6 B-D). Interestingly, 
reconstitution of Stat3
C/C 
mice with Stat3
WT/WT
 hematopoietic cells (C->WT) resulted in the 
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development of a more aggressive myocarditis than that observed in the C->WT transplanted mice. 
Heart infiltration by CD18
+
 cells and auto-antibody levels were similarly high in WT->C and C->C 
mice, while fibrosis was reduced (Fig. 6, B and D). The percentage of infiltrating CD11b
+
 cells was 
similar in the three groups as compared to the control WT->WT chimeras (Fig. 6 C). Despite 
similar death rates and age, the histopathological alteration observed in the WT->C and the C->C 
groups was reduced with respect to non-transplanted Stat3
C/C 
mice. This may be due to the early 
death after the transfer (between 12 and 15 days) that limited the accumulation and pathogenic 
action of the transplanted hematopoietic cells. These data clearly show that both hematopoietic and 
non-hematopoietic cells participate to the pathogenesis of myocarditis in the Stat3
C/C 
mice. 
Additionally, we observed that heart deposition of complement component C3 was different in the 
different groups of chimeras (Fig. 6 F). Interestingly, while C3 was almost undetectable in both 
groups of recipient wild type mice, we could detect comparably abundant C3 deposition in recipient 
Stat3
C/C
 mice transplanted with either wild type or Stat3
C/C
 bone marrow cells, correlating with their 
failure to survive. This observation suggests that C3 production, contributed by non hematopoietic 
Stat3
C/C 
cells, and its accumulation in the heart, may represent a crucial pathogenic factor in our 
model.  
 
Myocarditis is dependent on high C3 production. 
The above observation prompted us to examine the role of C3 in the pathogenesis of 
myocarditis in the Stat3
C/C
 mice. Indeed, C3 belongs to those serum proteins whose transcription is 
induced in the liver during the acute phase of inflammation, via IL-6-dependent STAT3 activation 
(Alonzi et al., 2001), and its pathogenic role is particularly relevant downstream of IL-6 during the 
early, inductive phases of EAM (Eriksson et al., 2003; Kaya et al., 2001). Interestingly, C3 mRNA 
levels were significantly elevated in the liver of Stat3
C/C
 mice compared to their wild type littermate 
controls even prior to disease development, correlating with significantly increased abundance of 
the circulating protein (Fig. 7, A and B). To assess the potential pathogenic role of C3 in our model, 
mice were treated with cobra venom factor (CVF) to achieve complement depletion (Kaya et al., 
2001). This did not affect the onset or severity of myocarditis in those Stat3
C/C
 mice already 
showing high C3 or anti--myosin antibodies at the time of treatment, in agreement with the 
predicted role of C3 in the inductive phase (Supporting Information Fig. S4A and B and Fig. 7 C). 
In contrast, almost 60% of the mice not yet displaying high C3 or auto-antibody levels were rescued 
by complement depletion (Supporting Information Fig. S4A and B and Fig. 7 C), showing 
significantly reduced auto-antibody titres, heart infiltration and fibrosis (Supporting Information Fig 
S4C-E). Thus, STAT3-dependent early C3 up-regulation may indeed represent a disease-initiating 
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factor occurring in the liver, as also supported by the observation that neither IL-17A neutralization 
nor CD4 depletion could reduce C3 circulating levels (Supplementary Information Fig. S5A and B). 
Accordingly, C3 could be detected by IF and IHC in the cardiac tissue of Stat3
C/C 
mice at just 2 
weeks of age, correlating with the increase of Gr1
+ 
cells and before the detection of CD4
+
 cells and 
the appearance of anti-myosin antibodies (Fig. 7 D and Supporting Information Fig S4F). Heart C3 
deposition progressively increased with disease development, followed by IgG deposition starting 
from 3 weeks of age, time of detection of the first CD4
+
 T lymphocytes infiltrating the heart (Fig. 7, 
D and E and Supporting Information Fig S4F). 
 
IL-6 receptor neutralization can significantly rescue myocarditis development 
Interestingly, the mRNAs encoding the STAT3-activating cytokine IL-6 and its alpha receptor (IL-
6R) were significantly increased in the hearts of infiltrated mice (Fig. 8 A and Supporting 
Information Fig S2). Additionally, the expression of the IL-6R mRNA was significantly increased 
in the liver of both infiltrated and non-infiltrated mice (Fig. 8 A), where it may lead to amplified IL-
6 signaling. Accordingly, IL-6 neutralization by means of anti-IL-6R antibodies could rescue 70% 
of the treated mice for up to 60 days of age (Fig. 8 B). Surviving mice showed virtually no auto-
antibodies and significantly reduced C3 levels, heart infiltration, fibrosis and STAT3 
phosphorylation, in keeping with the idea that inflammation, auto-immunity and C3 up-regulation 
are all dependent on IL-6 signaling and STAT3 activity (Fig. 8, C-F).  
 
IL-6 and C3 serum levels are highly correlated with heart STAT3 activation in human 
myocarditis 
Acute STAT3 activation is known to be beneficial in myocardial infarction, but its improper 
activation may be detrimental to heart function (Hilfiker-Kleiner et al., 2010). Accordingly, heart 
samples from human myocarditis patients clearly showed a massive infiltration of inflammatory 
cells, associated with strong STAT3 activation as assessed by IHC with phospho-specific STAT3 
antibodies (Fig. 9 A). Patients with acute myocarditis displayed elevated circulating IL-6 and C 
Reactive Protein levels (Fig. 9 B and C), which correlated with significantly higher circulating C3, 
compared to healthy controls or to samples from dilated cardiomyopathy or chronic myocarditis 
(Fig. 9 D). These observations suggest a correlation between inflammation, IL-6, STAT3 activity 
and C3 levels also in human myocarditis, particularly during the acute/inductive phase.  
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DISCUSSION 
STAT3 is well known to play both beneficial and pathogenic roles depending on its activation 
mode, i.e. tightly controlled as in physiological settings as opposed to aberrantly continuously 
active under pathological conditions such as chronic inflammation and cancer (Camporeale and 
Poli, 2012; Yu et al., 2009). In the heart, STAT3 was shown to be protective in myocardial 
infarction as well as in viral-induced myocarditis (Hilfiker-Kleiner et al., 2004; Lindner et al., 2012; 
Oshima et al., 2005; Yajima et al., 2011; Yajima et al., 2006). Conversely, Hilfiker-Kleiner et al. 
have reported that mice displaying heart-specific enhanced STAT3 activity due to the expression of 
a mutated intracytoplasmic sequence of mouse gp130 (gp130
Y757/fl
) showed excessive inflammatory 
responses and lethality upon myocardial infarction (Hilfiker-Kleiner et al., 2010). Continuous 
STAT3 activation is pathogenic also in our model, stressing the importance of a tight control over 
STAT3 activity. Differently from the gp130
Y757/fl
 mutants, our Stat3
C/C
 mice retain intact gp130 
signaling and, importantly, display whole body, low grade constitutive STAT3 activity (Barbieri et 
al., 2010). This triggers the development of an aggressive form of acute immune-mediated 
myocarditis requiring both enhanced IL-6 activity and C3 up-regulation, as shown by the IL-6 and 
complement neutralization experiments.  
Importantly, we could demonstrate that STAT3 is also a major player in the pathogenesis 
and progression of EAM. Indeed, EAM development was almost completely abrogated by 
treatment with the SF-1-066 STAT3 inhibitor. Moreover, STAT3 inhibition starting at the peak of 
heart inflammation showed therapeutic effects, as evidenced by the reduced diastolic dysfunction 
and by the failure of SF-1-066-treated mice to significantly modify either the myocardial 
performance index or the fractional shortening. Thus, continuous STAT3 activation appears to be 
an important pathogenic factor in the susceptibility to myocarditis, favoring its progression to DCM 
and heart failure. These findings are relevant to the human disease, as we could show that heart 
samples from acute myocarditis patients contain high levels of phosphorylated STAT3. These 
correlate with high systemic inflammation, as evidenced by the elevated levels of IL-6 and CRP, 
and significantly enhanced circulating C3 levels.  
Th17 CD4
+
 cells are believed to play an important role in the pathogenesis of EAM, 
although recent studies with IL-17A-deficient mice have shown that these cells are dispensable in 
the inflammatory phase (Baldeviano et al., 2010), suggesting at the same time an exacerbating role 
for Th1 and Th2 cells (Cihakova and Rose, 2008). In keeping with the known crucial function of 
IL-6 priming and STAT3 activity in Th17 cells differentiation (Harris et al., 2007; Haruta et al., 
2011; Nishihara et al., 2007; Zhou et al., 2007), we observed an expanded population of IL-17-
expressing cells in the spleen of the Stat3
C/C
 mice, correlating with increasingly abundant IL-17 in 
the hearts of Stat3
C/C
 mice.  Additionally, naïve Stat3
C/C
 T cells displayed a significantly enhanced 
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ability to differentiate along the Th17 lineage in vitro, even in the absence of IL-6. This is the first 
demonstration that aberrantly constitutive STAT3 activity is sufficient, both in vivo and in vitro, to 
skew the differentiation of CD4
+
 T lymphocytes towards the Th17 lineage. Despite these 
observations, Th17 cells do not appear to play a major role in the heart disease of the Stat3
C/C
 mice, 
since IL-17A neutralization could only protect 25% of the mice and only marginally affected heart 
infiltration, fibrosis and -myosin antibody levels. Interestingly, analysis of endomyocardial 
biopsies failed to detect IL-17-expressing T cells in samples from patients with both acute 
myocarditis and DCM, suggesting a minor role for Th17 cells in humans as well (Noutsias et al., 
2011). CD4 depletion was more effective in rescuing the disease in Stat3
C/C
 mice, albeit less than 
IL-6R neutralization or complement depletion, perhaps reflecting the role of other CD4
+
 T cells 
populations. Indeed, both Th1 and Th2 cells have been reported to be able to concur to myocarditis 
pathogenesis in EAM, although Th-1-produced IFN appears to be protective (Afanasyeva et al., 
2005; Afanasyeva et al., 2001; Cihakova and Rose, 2008; Daniels et al., 2008). Interestingly, 
neither IL-17 neutralization nor CD4 depletion could alter the up-regulation of C3 observed in the 
Stat3
C/C
 mice. 
The expansion of the CD11b
+
/Gr1
+
 cell population, already observed in the blood and bone 
marrow of non infiltrated animals, and whose accumulation in the heart occurs before CD4
+
 cells 
detection, is likely to contribute to disease pathogenesis. This disruption in myeloid cells 
homeostasis may participate in the initial damage as well as contribute to the production of 
inflammatory cytokines. Myeloid cells have been proposed to play a role in EAM (Blyszczuk et al., 
2009; Cihakova and Rose, 2008) and may also contribute to enhance C3 local production in the 
heart (Botto et al., 1992; Tsukamoto et al., 1993). 
The experiments with bone marrow chimeras have shown that the fully-fledged disease can 
only develop when both hematopoietic and non-hematopoietic cells display constitutive STAT3 
activity, and both lethality and C3 deposition appear to correlate with the expression of the Stat3
C/C
 
allele in non hematopoietic cells. Among these, our results suggest a central role for the 
hepatocytes. Indeed, the observation that IL-6R expression is up-regulated in the livers of Stat3
C/C
 
mice prior to disease onset suggests local amplification of IL-6 signaling, in agreement with the 
previously observed up-regulation of several liver acute phase mRNAs (Barbieri et al., 2010). 
Indeed, STAT3 is well known to be part of a pro-inflammatory loop involving IL-6 and NF-kB, 
thought to play an important role in inflammation-related cancer (Karin and Greten, 2005; Yu et al., 
2009) as well as in auto-immunity (Camporeale and Poli, 2012). IL-6 signaling amplification may 
in turn explain the enhanced liver expression of the acute phase protein C3, leading to its early heart 
localization observed in the Stat3
C/C 
mice before disease development. Together with the rescue 
obtained upon IL-6R neutralization and complement depletion, and the knowledge that C3 plays a 
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pathogenic role in the inductive phase of EAM, downstream of IL-6 (Eriksson et al., 2003; Kaya et 
al., 2001) our results suggest that IL-6/STAT3-mediated enhanced C3 production in the liver is 
instrumental in disease initiation. This may be further amplified by local production of C3 by the 
infiltrating cells themselves, as both myeloid and CD4
+
 T cells are known to be able to express this 
protein (Botto et al., 1992; Kwan et al., 2012; Tsukamoto et al., 1993). As C3 can act as a chemo-
attractant, its presence in the heart is likely to initiate a feed-forward loop, progressively attracting 
increasing numbers of inflammatory cells, and leading to heart muscle damage.  
Death directly linked to acute myocarditis can be a serious clinical problem, particularly in 
developing countries (Feldman and McNamara, 2000). Moreover, heart inflammation is a relevant 
component of many other cardiac diseases, and myocarditis is considered one of the leading causes 
of idiopathic DCM and heart failure. However, what factors determine the switch between disease 
resolution and progression are at present incompletely understood, and the ability to identify 
individuals at greater risk of developing aggressive heart inflammation and to predict clinical 
development would improve patients care. In this light, our results suggest the idea that pre-existing 
inflammatory conditions not localized to the heart, increasing C3 production via an IL-6-STAT3 
loop in the liver, might play a relevant pathogenic role in the onset of immune-mediated 
myocarditis. Moreover, the therapeutic effects of STAT3 neutralization in EAM suggest that this 
factor may also play a role in myocarditis progression to DCM. This mechanism may be relevant 
for human acute myocarditis patients as well, where we were able to demonstrate strong cardiac 
STAT3 activation correlating with high circulating IL-6 and with significantly elevated C3 levels. 
Further clinical correlation studies will be needed to establish whether circulating C3 levels might 
become a useful tool to help predicting susceptibility to aggressive myocarditis, and possibly its 
progression to DCM and heart failure. 
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METHODS 
Animals and analysis 
Generation of the Stat3
C/C
 mice was previously described (Barbieri et al., 2010). The mice used 
were in the Balb/C background (F8 backcross). Mice were maintained in the transgenic unit of the 
Molecular Biotechnology Center (University of Turin) under a 12-h light-dark cycle and provided 
food and water ad libitum. Procedures were in conformity with national and international laws and 
policies as approved by the Faculty Ethical Committee. Mice were inspected and weighed every 
three days, and sacrificed by cervical dislocation. 
 
Flow cytometry 
To isolate infiltrating cells, hearts were disaggregated with collagenase type 2 and protease type 
XIV (Sigma-Aldrich, St. Louis MO, USA) as described. A FACScalibur flow cytometer (BD 
Bioscience, Franklin Lakes, NJ USA) and the cell quest software were used, with FITC anti-Gr1 
and PE anti-CD11b antibodies (BD Bioscience). Intra-cellular cytokine staining was performed 
upon PMA/ionomycin and Brefeldin A treatment, followed by labelling with FITC anti-CD4 mAb 
(BD Bioscience), fixation in 2% paraformaldehyde, permeabilization with 0.1% saponin-1% FCS-
PBS, and incubation with cytokine-specific mAbs (BD Bioscience).  
 
Ex-vivo cytokines production 
Splenocytes were incubated in RPMI medium (Invitrogen, Carlsbad CA, USA) supplemented with 
10% FBS (Invitrogen), penicillin and streptomycin, and stimulated as previously described 
(Veldhoen et al, 2006) followed by intracellular flow cytometry. 
 
In vitro T cell differentiation assay 
CD4
+
 naïve T cells were isolated from the spleens using the CD4
+
 CD62L
+
 T cell isolation kit II 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were cultured in anti-CD3, anti-CD28 (BD 
Bioscience)-coated 24 multi-wells plates for 3 days in RPMI 1640 containing 10% heat-inactivated 
FCS, 50 μM 2-mercaptoethanol, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 100 
units/ml penicillin, and 100 μg/ml streptomycin (Veldhoen et al, 2006) (Invitrogen) treated with 
5ng/ml TGF (Peprotech, Rocky Hill, NJ, USA), with 10 g/ml anti-IFN (BD Bioscience) and 
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with or without 20 ng/ml IL-6 (Peprotech, Rocky Hill, NJ, USA) for Th17 differentiation, with 20 
ng/ml IL-12, 20 ng/ml IL-2 and with 10 g/ml anti-IL-4 (Peprotech, Rocky Hill, NJ, USA) for Th1 
differentiation, with 50 ng/ml IL-4, 20 ng/ml IL-2 (Peprotech, Rocky Hill, NJ, USA) and 10 g/ml 
anti-IFN for Th2 differentiation, without cytokines for Th0 condition followed by IL-17 or IFN or 
IL-4 intracellular staining and flow cytometry. 
 
Experimental auto-immune myocarditis 
8 weeks old Balb/C mice were immunized essentially as described (Sonderegger et al., 2006) with 
the -myosin heavy chain peptide Myhc-614-634 (AnaSpec corporation, Fremont, CA, USA) or 
saline solution, emulsified 1:1 in Freund’s complete adjuvant (CFA; Difco Laboratories, Detroit, 
Michigan, USA). 3 mg/kg of the STAT3 inhibitor SFI-066 (Zhang et al, 2010,  provided by Prof. P. 
Gunning) were injected i.p. every 3 days starting from day 0 or day 21 of immunization. 
Appropriately diluted DMSO was used as control. 
 
ELISA assays 
Anti-cardiac -myosin IgG1 were measured upon coating with 3 μg/ml of cardiac myosin prepared 
as described (Shiverick et al., 1975), followed by incubation with mouse sera and HRP-labeled rat 
anti-mouse IgG1 (BD Bioscience). Murine C3 was captured with a polyclonal goat-IgG to mouse 
C3 and revealed with the same antibody peroxidase-conjugated (Cappel, ICN Pharmaceuticals, 
Costa Mesa, California, USA). SAP (Serum Amyloid P Component, Normal Mouse standard, 
Calbiochem, San Diego, CA, USA), was used as a standard according to manufacturer’s 
instructions. Human CRP was determined by Beckman Synchron LX-20 analysis. Human C3 was 
measured by nephelometry with a goat anti-human antiserum.  
 
Lymphocytes proliferation assay 
CD4
+
 T cells were isolated from spleens of immunized mice using the CD4 (L3T4) MicroBeads 
mouse kit (Miltenyi Biotec), and co-cultured for 72 hours with 200,000 mitomycin A-treated 
syngeneic splenocytes (APCs) pre-cultured with Myhc-614-634 peptides (1mg/10
6
 cells). Cells were 
then pulsed with 0.5 Ci of [
3
H] methyl-thymidine (Perkin Elmer, MA, USA) for 16 hours and 
proliferation evaluated by thymidine incorporation. 
 
BM Transplantation 
Three weeks (Stat3
C/C
) or eight weeks (Stat3
WT/WT
) old mice were subjected to lethal total body 
irradiation (2.5 or 5 Gy, respectively) administered twice with 3 hours interval, followed by the IV 
injection of 10*10
6
 bone marrow-derived cells from donor mice one hour post-irradiation. 
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Transplantation rate was assessed by quantitative Sybr Green PCR on peripheral blood genomic 
DNA. Chimeric animals with less than 80% of circulating donor cells were excluded from the 
analysis. 
 
In vivo depletion and IL-6 administration 
Stat3
C/C
 mice were injected i.p. with 100 g of anti-CD4 mAbs (Ibridoma GK1.5) or with 100 g of 
purified rat mAb anti-mIL-17A, which recognizes both IL-17A and the IL-17A/F heterodimer (Rat 
IgG, R&D system, Minneapolis, MN, USA) or s.c. with 240 g of the anti-IL-6Ralpha 15A7 mAb 
(Vink et al., 1990), once a week starting from two weeks of age. Control mice received isotype-
matched IgG rat mAb (R&D system). CD4 depletion was assessed by flow cytometry on peripheral 
blood. 
1U/mouse of cobra venom factor (CVF, Sigma-Aldrich) was injected i.p. every second day for ten 
days starting from day 21 after birth as previously described (Kaya et al., 2001).  
 
Histological and immunohistochemical analysis  
Hearts were fixed in 4% paraformaldehyde for 24h, paraffin-embedded, and sections stained with 
hematoxylin-eosin or incubated overnight with rat anti-mouse CD18 (BMA Biomedicals, Augst, 
CH) followed by biotinylated or HRP anti-rat IgG (Dako Cytomation, Carpinteria, CA, USA). 
Antibodies for MAC3 and CD4 (BD Bioscience), MPO (Dako Cytomation), STAT3 (Santa Cruz 
Biotechnology, Santa Cruz CA, USA) and P-STAT3 (Cell Signaling Technology, Danvers MA, 
USA) were used on frozen sections after cold acetone fixation. Collagen fibres were evidenced by 
Picrosirius red staining (Fluka-Sigma Aldrich). Quantification was performed using Metamorph 
software (Universal Imaging Corporation), averaging at least 8 fields per sample. 
 
Immunofluorescence and confocal microscopy. 
Hearts were fixed in 4% paraformaldehyde for 4 hours, dehydrated in 30% sucrose overnight and 
frozen in OCT. Sections (40 m) were permeabilized with 0.3% Triton X-100 in PBS and 
incubated with primary antibodies for IL-17, CD4, Gr1 (BD Bioscience), C3 (Abcam, Cambridge, 
UK), IgG (Dako Cytomation), -actinin and cx43 (Sigma-Aldrich), followed by Cy3 or AlexaFluor 
labelled secondary antibodies (Sigma-Aldrich). Rat adult cardiomyocytes were fixed in 4% 
paraformaldehyde and stained with mouse sera, followed by AlexaFluor-labeled secondary 
antibody (Sigma-Aldrich). Images were acquired using an Olympus Fluoview 200 laser scanning 
confocal system (Olympus Inc., Germany) mounted on an inverted IX70 Olympus microscope, 
equipped with a 60X Uplan Fl (NA 1.25) oil-immersion objective. Image processing and analysis 
were performed with ImageJ software (Rasband WS, Image J, US National Institutes of health, 
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Bethesda). The Cell Counter plugin was used to quantify cell numbers, while for intensity 
quantification of staining we used images acquired with the same brightness/contrast parameters. 
 
 
Real time PCR 
Total RNA was prepared with the PureLink Micro-to-Midi total RNA Purification System 
(Invitrogen). qRT-PCR reactions were performed as previously described  using the Universal 
Probe Library system (Roche Diagnostic, Mannheim, Germany). Probes and oligonucleotide 
sequences used are reported in the supplementary table III. The 18S rRNA pre-developed TaqMan 
assay (Applied Biosystems, Carlsbad, California, USA) was used as an internal control. 
 
Western blot, Immunoprecipitation and mass spectrometry 
Total protein extracts (Maritano et al., 2004), were fractionated on SDS-PAGE and transferred to a 
polyvinylidene difluoride membrane (Millipore, Schwalbach, Germany). For immunoprecipitation, 
protein extracts were pre-cleared with protein G/A beads (GE Healthcare, New Jersey, USA), then 
precipitated with mouse serum, Myh-6 (a kind gift from Prof. Stefano Schiaffino, University of 
Padua) and My-BPC3 (Santa Cruz Biotechnology) antibodies and protein G beads, overnight at 
4°C. MALDI mass spectrometry was performed as described . 
 
Echocardiography 
Echocardiography was performed in conscious mice with a GE System 5 echocardiograph. Stat3
C/C 
mice were anesthetized with 5 mg/kg of Zoletil 100 (Virbac, Milan, Italy), instead Balb/C mice 
with EAM with isofluorane. Mice were analyzed with a Vevo2100 High Resolution Imaging 
System (Visual Sonics Inc, Toronto, Ontario, Canada) with the transducer MS550D. From the 2D  
long-axis  were derived left ventricle M-mode: eft ventricle systolic and diastolic diameters (LVES  
and LVED), systolic and diastolic septum and posterior wall thickness (IVST and PWT) were 
measured. FS was calculated as (LVED-LVES)/LVED %. Pulsed Doppler on mitral flow was 
registered and E, A velocities and DT were measured. The ratio E/A were calculated. By tissue 
Doppler at the basal level of lateral wall were collected E’ and A’ velocities and their ratio E/E’. 
Diastolic function was defined as normal if E/A >1, E’/A’>1, DT < 20 ms; I degree of dysfunction 
if E/A < 1, E’/A’<1, DT > 20 ms; II degree of dysfunction if E/A >1, but E’/A’ <1 and DT > 20; III 
degree of dysfunction if E/A > 2 and DT< 20 ms with reduced E’ and A’ velocities. 
 
Statistics  
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The unpaired two–tail Student’s t–test with Welch’s correction was used for comparisons between 
two groups of samples and in all echocardiographic analysis. One-way analysis of variance 
(ANOVA) with Tukey's HSD Post-hoc test was used for comparing three or more groups. A two-
way analysis of variance (ANOVA) with Tukey's HSD Post-hoc test was used to analyse animal 
weights and in vitro Th17 differentiation. The Logrank Mantel-Cox test was used for significance 
of survival curves. P values lower or equal to 0.05 were considered significant.  
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THE PAPER EXPLAINED 
 
PROBLEM: 
Myocarditis, or inflammation of the heart muscle, is linked to the development of heart auto-
immunity and can progress to dilated cardiomyopathy and heart failure in as much as one third of 
the cases. Disease management lacks of reliable diagnostic procedures and of specific therapeutic 
strategies, particularly because little is know of the factors determining the switch between disease 
resolution and progression. 
 
RESULTS: 
Both IL-6 and IL-17 are thought to play a pathogenic role in auto-immune diseases and in particular 
in immune-mediated myocarditis. We show that pharmacological inhibition of the transcription 
factor STAT3, the main mediator of IL-6 functions and also essential for Th17 cells differentiation, 
abolishes the development of Experimental Auto-immune Myocarditis in mice, and can even act 
therapeutically when administered at disease peak, reducing the degree of cardiac dysfunction. This 
effect correlates with impaired myosin-specific CD4
+
 T lymphocytes responses and with reduced 
production of the complement component C3, a known pathogenic factor in the early phases of the 
disease. We then demonstrate that systemic constitutively active STAT3 is sufficient to trigger an 
aggressive form of immune-mediated myocarditis requiring STAT3-mediated up-regulation of C3 
in the liver, and correlating with Th17 cells expansion. Indeed, disease development can be 
prevented by both depleting C3 and neutralizing IL-6R, whose signaling is amplified in the liver. In 
contrast, Th17 cells appear to only play a limited role. This mechanism may be relevant for the 
human disease, where we were able to demonstrate strong cardiac STAT3 activation correlating 
with high circulating IL-6 and with significantly elevated C3 levels in acute myocarditis patients. 
 
IMPACT: 
IL-6 production and STAT3 activity are a hallmark of inflammation, acute or chronic, which 
impinges on the liver triggering the up-regulation of several plasma proteins including C3. Our data 
suggest that pre-existing inflammatory conditions involving IL-6/STAT3-mediated activation of the 
liver inflammatory response and C3 up-regulation may represent one of the factors determining the 
progression of myocarditis to DCM and heart failure. Further clinical correlation studies will be 
needed to establish whether circulating C3 levels might become a useful tool to help predicting 
susceptibility to aggressive myocarditis, and possibly its progression to DCM and heart failure. 
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FIGURE LEGENDS 
Figure 1. EAM development is dependent on STAT3 activity. Wild type Balb/C mice were 
immunized with an -myosin peptide as described in the Materials and Methods section, with or 
without STAT3 inhibition via i.p. injection of SF-1-066. SF-1-066 was either administered from 
day 0, and mice sacrificed at day 21 (A-D), or from day 21, and mice sacrificed at day 42 (E-F). 
Data are plotted as mean±SEM of three independent experiments. 
A. Flow cytometry of CD11b+ infiltrating cells. The hearts of untreated (white bars, n=11) or 
SF-1-066-treated mice (black bars, n=8) were analysed. **P=0.002.  
B. Analysis of representative heart samples of mice from A. The indicated stainings were 
performed. Scale bar: 50 m, with the exception of the 2x magnification photomicrographs 
(left panels), where the scale bar is 500 m.  
C. C3 ELISA and anti-myosin IgG1. Sera from untreated (white bars, n=5) and SF-1-066-
treated (black bars, n=5) mice with EAM at the indicated days after immunization were 
analysed. C3, *P=0.027; -myosin IgG, *P=0.024. 
D. T lymphocytes proliferation assay. Thymidine incorporation was measured on splenic CD4+ 
cells isolated from the above mice, upon three days of stimulation with APCs pulsed with -
myosin peptide. ***P=0.0006. 
E. Echocardiographic analysis was performed on Balb/C mice with EAM, either untreated 
(white bars, n=4) or treated (black bars, n=4) iv with the SF-1-066 STAT3 inhibitor, starting 
at day 21 post-immunization. Diastolic dysfunction grade was assessed using pulsed 
Doppler echocardiography and measuring the left ventricular filling velocity (E/A, ratio of 
left ventricular filling velocities during early and late diastole), the left ventricular filling 
pressure (E/E’, ratio of transmitral and annular velocities) and the decelerating time (DT) as 
described in the Methods section. **, untreated mice, day 21 vs day 42, =0.0138; untreated 
vs treated mice, day 42, P=0. 
F. Myocardial Performance Index (MPI) or Tei index was calculated in the same groups as in E 
from a ratio of time intervals (a-b/b) derived with the pulsed Doppler echocardiography, 
where “a” is the interval time between the end and the start of transmitral flow and “b” is the 
left ventricular ejection time. *, untreated mice, day 0 vs day 42, P=0.0191; untreated vs 
treated mice, day 42, P=0.0361. 
G. Fractional shortening (FS) was measured in the same groups as in E using M-mode image of 
left ventricle and calculated as (LVEDd-LVESd)/LVEDd expressed as a percentage 
(LVEDd=left ventricular end-diastolic diameter; LVESd= left ventricular end-systolic 
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diameter). *, untreated mice, day 0 vs day 42, P=0.0313; untreated mice, day 21 vs day 42, 
P=0.0440. 
 
Figure 2. Myocarditis development in Stat3
C/C 
mice.   
A. Growth curves. 12 Stat3WT/WT (black circles) and Stat3C/C littermates (black squares) were 
weighed every 3 days starting from the day of birth. ***P<0.0001. 
B. Kaplan-Meier survival curves of Stat3C/C (red line) and Stat3WT/WT (black line) mice (n=32). 
***P<0.0001. 
C. Cytofluorimetric analysis. Data are shown as mean±SEM of infiltrating CD11b+Gr1- and 
CD11b
+
Gr1
+
 cells in the hearts of Stat3
WT/WT
 (white bars, n=41), non-infiltrated (grey bars, 
n=17) and infiltrated (black bars, n=29) Stat3
C/C  
mice. ***P<0.0001. 
D. Histological, histochemical and immunohistochemical analysis. Hearts from Stat3WT/WT or 
infiltrated Stat3
C/C 
mice were stained as indicated: hematoxilin and eosin (H&E), picrosirius 
red, or antibodies against myeloperoxidase (MPO), CD18, CD4, STAT3, P-STAT3. Pictures 
are representative of at least three mice per group. Scale bar: 50 m.  
 
Figure 3. Immunofluorescence analysis of heart infiltration and morphology. Hearts were 
dissected from Stat3
C/C 
or Stat3
WT/WT
 mice at the indicated weeks of age and stained with the 
indicated antibodies. Pictures are representative of four to six mice per group. Histograms represent 
the quantification of fluorescence intensity (mean±SEM). Scale bar: 50 m. ***P<0.001; 
**P<0.01; *P<0.05. 
A. anti-CD4, green; anti-alpha actinin, red. 
B. anti-Gr1, green; anti-alpha actinin, red. 
C. anti-connexin (cx) 43, red;  anti-alpha actinin, green.  
 
Figure 4. Heart auto-immunity in infiltrated Stat3
C/C 
mice.  
A. Immunoblot analysis of total protein extracts from heart (H), skeletal muscle (SK M) or 
kidney (K) with sera from individual Stat3
WT/WT 
(WT)
 
and Stat3
C/C 
(C)
 
mice. The degree of 
infiltration is shown.  
B. IF analysis of rat cardiocytes with sera from Stat3WT/WT and Stat3C/C mice. Red: serum 
decorated with anti-mouse fluorescent antibody; green: phalloidin. Note the strong red 
staining obtained with Stat3
C/C 
serum, marking a sarcomeric-organized component that 
partially superimposes with the green phalloidin labelling of actin, resulting in a repetition 
of yellow bands (arrows), absent in the cell labelled with Stat3
WT/WT
 serum. 
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C. Preparative gel for mass spectrometry. Whole heart extracts were immunoprecipitated with 
pooled sera and fractionated on SDS page followed by Coomassie staining. Bands indicated 
by asterisks were excised and analysed by Mass Spectrometry.  
D. Whole heart extracts were immunoprecipitated followed by immunoblotting with the 
indicated sera/antibodies. Data are representative of two to three experiments with 
individual sera. The asterisks indicate non specific signals. 
E. Myosin-specific IgG1 ELISA. Sera from Stat3WT/WT (white bars, n=28), non-infiltrated (grey 
bars, n=22) and infiltrated (black bars, n=20) Stat3
C/C 
mice were used. Bars represent 
mean±SEM of values expressed as arbitrary units (A.U.). ***P<0.0001. 
 
Figure 5. Stat3
C/C 
mice are more prone to Th-17 differentiation.  
A. Cytofluorimetric analysis of IL-17 producing CD4+ T cells in the spleen of Stat3WT/WT 
(white bars, n=6) and Stat3
C/C 
(black bars, n=6) mice. Data are shown as meanSEM. 
*P=0.015 .  
B. In vitro differentiation of Th17 cells. Naïve CD4+ cells were purified from spleens of 
Stat3
WT/WT
 (white bars, n=6) and Stat3
C/C 
(black bars, n=10) mice and treated or not with 
TGF, IL-6 and anti-IFN, followed by cytofluorimetric analysis for CD4 and IL-17. Data 
are shown as meanSEM.  **P=0.001.  
C. In vitro differentiation of Th17 cells without IL-6. Naïve CD4+ cells were purified from 
spleens of Stat3
WT/WT
 (white bars, n=6) and Stat3
C/C 
(black bars, n=6) mice, treated or not 
with TGF and anti-IFN and analysed as above. Note the different scales between B and C. 
Data are shown as meanSEM. **P=0.006 (Stat3WT/WT vs Stat3C/C cells); *P=0.025 
(untreated vs treated Stat3
C/C
 cells).  
D. Taqman RT-PCR analysis on total RNA from the spleen of Stat3WT/WT (white bars, n=7) and 
Stat3
C/C 
(black bars, n=7) mice. Data are shown as meanSEM. *P=0.018 (RORt); 
**P=0.0057 (IL-23).  
E. IL-17 (red) and CD4 (green) IF staining of hearts from Stat3WT/WT (WT) and Stat3C/C (C) 
mice at the indicated weeks of age. Representative samples of three mice per group are 
shown. Scale bar: 50 m.  
F. Kaplan-Meier survival curves of Stat3C/C mice treated with anti-IL-17 neutralizing mAbs 
(red line, n=7) or with total IgG as controls (black line, n=4).  
G. IL-17 (red) and CD4 (green) IF staining of hearts from anti IL-17-treated and control mice 
as above. Representative samples from survived (n=2) or diseased (n=5) mice are shown. 
Scale bar: 50 m. 
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H. Kaplan-Meier survival curves of Stat3C/C mice treated with anti-CD4 neutralizing mAbs (red 
line, n=13) or with total IgGs as controls (black line, n=10). *P=0.026. 
I. The hearts of mice from H were analyzed as indicated. IgG, control mice; for the aCD4-
treated mice, samples from survived mice are shown on the left, and those from dead mice 
on the right. Scale bar: 50 m. 
 
Figure 6. Both hematopoietic and non-hematopoietic compartments are involved in 
myocarditis development.  
A. Kaplan-Meier survival curves showing survival of bone marrow chimeras. control 
Stat3
WT/WT
-> Stat3
WT/WT
, black line, n=14; Stat3
C/C
->Stat3
WT/WT
, green line, n=15; 
Stat3
WT/WT
->Stat3
C/C
, orange line, n=9; and control Stat3
C/C
-> Stat3
C/C
, red line, n=6.  
B. Representative heart histochemical analysis of mice from A. Scale bar: 50 m. 
C. Heart-infiltrating CD11b+ cells measured by flow cytometry in mice from A, shown as 
mean±SEM of percentages of CD11b
+
 cells. Stat3
WT/WT
-> Stat3
WT/WT 
(white bars, n=14); 
Stat3
C/C
->Stat3
WT/WT 
(grey bars, n=15); Stat3
WT/WT
->Stat3
C/C 
(dark grey bars, n=10) and 
Stat3
C/C
->Stat3
C/C 
(black bars, n=4). 
D. Myosin-specific serum IgG1 levels measured by ELISA in mice from A, shown as 
mean±SEM of values expressed as arbitrary units. Bars as in C, numbers as in A.  
E. The relative abundance of the STAT3WT (white bar) and STAT3C (black bar) alleles was 
measured by SYBR Green real time PCR in the blood of transplanted mice at the time of 
sacrifice. 
F. IF analysis of C3 deposition in the hearts of mice from C. Pictures are representative of six 
mice per group. Scale bar: 50 m. 
 
Figure 7. Pathogenic role of C3.  
A. C3 protein levels measured by ELISA in the serum from Stat3WT/WT (white bars, n=26), non-
infiltrated (grey bars, n=26) and infiltrated (black bars, n=28) Stat3
C/C
 mice. Data are shown 
as meanSEM. *P= 0.034; ***P<0.0001.   
B. C3 mRNA levels measured by Taqman RT-PCR on liver RNA from the same mice as in A. 
Data are shown as meanSEM. *P=0.013 (Stat3WT/WT vs non-infiltrated Stat3C/C); 
**P=0.0086 (Stat3
WT/WT 
vs infiltrated Stat3
C/C
).  
C. Survival curves of mice after in vivo complement depletion. CVF-treated Stat3WT/WT (black 
line, n=8), non-infiltrated (orange line, n=7) and infiltrated (red line, n=12) Stat3
C/C
 mice 
were analysed. ***P<0.0001.  
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D. IF analysis of C3 localization in the hearts of Stat3C/C and Stat3WT/WT mice at the indicated 
ages in weeks. Green: CD4; Red: C3. Pictures are representative of six mice per genotype. 
Scale bar: 50 m. 
E. Immunofluorescence analysis of IgG deposition (in red) in the same samples from D. Scale 
bar: 50 m. 
 
Figure 8. Pathogenic role of IL-6.  
A. IL-6Ra mRNA levels (meanSEM of normalized values) were measured by Taqman RT-
PCR in the hearts or livers of Stat3
WT/WT 
(white bars, n=10), non-infiltrated (grey bars, n=9) 
and infiltrated (black bars, n=8) Stat3
C/C
 mice. * heart, Stat3
WT/WT 
vs non-infiltrated Stat3
C/C
, 
P=0.034; heart, Stat3
WT/WT 
vs infiltrated Stat3
C/C
, P=0.008; ** liver, Stat3
WT/WT 
vs non-
infiltrated Stat3
C/C
, P=0.002; liver, Stat3
WT/WT 
vs infiltrated Stat3
C/C
, P=0.001.  
B. Kaplan-Meier survival curves of Stat3C/C mice treated with anti-IL-6R-neutralizing 
antibodies (red line, n=7) or with total IgGs( black line, n=10) as control, starting from two 
weeks of age. **P=0.0058.  
C. Flow cytometry of CD11b+ heart-infiltrating cells in mice from B. Results are shown as 
mean±SEM of the percentage of positive cells. IgG-treated (white bars, n=5); surviving anti-
IL6R-treated (black bars, n=3).  
D. Anti-myosin IgG1 ELISA in mice from B. Results are shown as mean±SEM of signal 
intensity in arbitrary units (A.U.) in the sera from IgG-treated (white bars, n=10) and 
surviving anti-IL6R-treated (black bars, n=5) Stat3
C/C 
mice, sacrificed at 60 days of age. 
**P=0.0073 
E. Circulating C3 ELISA. The same sera as in D were analysed. **P=0.0011. 
F. Representative heart histochemical analysis of mice from C. Scale bar: 50 m. 
 
Figure 9. STAT3 phosphorylation and elevated circulating IL-6, CRP and C3 levels in human 
myocarditis.  
A. Immunohistochemical analysis. Hearts from human patients with myocarditis or from non-
myocarditis controls, using antibodies detecting total (STAT3) or tyrosine-phosphorylated 
(P-STAT3) STAT3. Pictures are representative of three to five different patients. Scale bar: 
50 m. 
B. IL6 ELISA. Circulating IL-6 (mean±SEM) levels were measured in the serum from healthy 
individuals (white bars, n=10), or from patients with dilated cardiomyopathy (DCM, light 
grey bars, n=9), chronic myocarditis (dark grey bars, n=8) and acute myocarditis (black 
bars, n=7). ***P<0.0001 (Healthy vs Acute, DCM vs Acute, Chronic vs Acute). 
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C. CRP ELISA on the same samples as in B. ***P<0.0001 (Healthy vs Acute, DCM vs Acute, 
Chronic vs Acute). 
D. C3 ELISA on the same samples as in B. **P=0.0054 (Healthy vs Acute); *P=0.026 (DCM 
vs Acute); **P=0.0087 (Chronic vs Acute). 
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